How to access Alunbrig from Kuwait — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Kuwaiti patient with ALK-positive non-small-cell lung cancer (NSCLC) may receive a prescription for Alunbrig (brigatinib) from their treating medical oncologist, either as first-line therapy or after progression on crizotinib or another earlier ALK inhibitor. Alunbrig is FDA-approved in the United States and is a recognised option for ALK-positive NSCLC. In Kuwait, Alunbrig may not be routinely stocked in hospital pharmacies across all specialties, which is why your oncologist may be coordinating a named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Alunbrig is a second-generation oral ALK tyrosine kinase inhibitor with activity against a range of ALK resistance mutations and CNS disease. Eligibility requires molecular confirmation of an ALK rearrangement. The manufacturer is Takeda. Dosing typically uses a 7-day lead-in at 90 mg once daily before escalating to 180 mg once daily, to reduce risk of early-onset pulmonary events. Monitoring includes pulmonary symptoms in the first week, hypertension, bradycardia, hyperglycaemia, and CPK elevation. Your oncologist will confirm ALK status and sequencing against your overall treatment plan.
Is Alunbrig legally importable into Kuwait?
Yes — through the Kuwait Ministry of Health (MOH) named-patient import framework, administered through the hospital's importing pharmacy and the MOH Drug and Food Control Department. Kuwait has a mature named-patient mechanism that supports cross-border access to specialised oncology products.
The framework rests on four anchors: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. Applications are typically filed by the tertiary centre's importing pharmacy on the physician's behalf.
How the pathway works, step by step
- Consultation with your treating oncologist. The decision to prescribe Alunbrig is a clinical one. Your oncologist documents ALK status, prior therapy history, and clinical rationale.
- Administering facility identification. A Kuwaiti tertiary oncology centre with an importing pharmacy files on behalf of the physician.
- MOH named-patient application. Your physician or the hospital's importing pharmacy files an application with the MOH Drug and Food Control Department including clinical rationale, patient identifier, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
- Temperature-controlled shipment. Alunbrig is a stable oral tablet; shipments travel with tamper-evident packaging and end-to-end documentation.
- Arrival and dispensing support. Your oncologist remains the treating clinician. Reserve Meds coordinates re-supply ahead of cycle end to avoid treatment gaps.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming ALK status, prior therapies, and Alunbrig as the indicated treatment
- Verification of their Kuwait medical licence (MOH)
- A current prescription naming the product, strength, and quantity
- Patient identifier (anonymised reference preferred)
- The planned treatment cadence (lead-in then continuous therapy with monthly re-supply)
Reserve Meds provides a physician documentation kit that bundles the templates Kuwait MOH reviewers expect to see for oncology oral therapies under named-patient import.
Costs and timing
Alunbrig's US cash-pay reference price for a 30-day supply sits in an indicative 2026 range of roughly USD 18,000–21,000. Logistics, MOH documentation handling, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first shipment arrival after cohort intake opens is approximately 14–28 days from the moment a complete MOH application is submitted. Subsequent re-supply cycles are generally faster once the pathway is established.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Alunbrig specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for Kuwait MOH review.
- Logistics. Temperature-stable shipment and chain-of-custody coordination.
- Concierge case lead. A named point of contact for your family and your physician throughout the process.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in Kuwait? Yes, when executed through the Kuwait MOH named-patient framework with appropriate documentation. The pathway has been used routinely across oncology for many years. See our trust and compliance page.
What about the first-week pulmonary monitoring? Alunbrig's 7-day lead-in dose exists to reduce the risk of early-onset pulmonary events. Your oncologist will outline the monitoring plan for that window; we coordinate supply, not treatment.
What if my oncologist has not done this before? Named-patient import is an institutional process your oncologist's hospital will have encountered. Our documentation kit closes the gap for first-time applicants.
Will private insurance cover this? Cash-pay is the default. Some Kuwaiti private insurers reimburse named-patient imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Alunbrig coordination in Kuwait.
Add me to the Alunbrig waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.